Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
Open Access
- 6 November 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 9 (11), 277-294
- https://doi.org/10.1177/1759720x17735756
Abstract
Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38).Keywords
This publication has 120 references indexed in Scilit:
- Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque PsoriasisPLOS ONE, 2012
- IL-35 Is a Novel Responsive Anti-inflammatory Cytokine — A New System of Categorizing Anti-inflammatory CytokinesPLOS ONE, 2012
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- IL-9 induces differentiation of T H 17 cells and enhances function of FoxP3 + natural regulatory T cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- IL-21 and TGF-β are required for differentiation of human TH17 cellsNature, 2008
- Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cellsThe Journal of Experimental Medicine, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammationJCI Insight, 2008
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007